These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 33801379)

  • 41. EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.
    Fichter CD; Timme S; Braun JA; Gudernatsch V; Schöpflin A; Bogatyreva L; Geddert H; Faller G; Klimstra D; Tang L; Hauschke D; Werner M; Lassmann S
    Int J Cancer; 2014 Oct; 135(7):1517-30. PubMed ID: 24510732
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer.
    Mishima S; Shitara K
    Expert Opin Biol Ther; 2021 Jul; 21(7):825-830. PubMed ID: 33798395
    [No Abstract]   [Full Text] [Related]  

  • 43. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
    Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
    Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
    Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
    Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy.
    Shi F; Liu Y; Zhou X; Shen P; Xue R; Zhang M
    Drug Deliv; 2022 Dec; 29(1):1335-1344. PubMed ID: 35506447
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Current Treatment Standards and Future Perspectives.
    Dormann C
    Breast Care (Basel); 2020 Dec; 15(6):570-578. PubMed ID: 33447230
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Future of HER2-Targeted Treatment for Osteosarcoma: Lessons from the Negative Trastuzumab Deruxtecan Results.
    Nakano K
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069146
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer.
    Najjar MK; Manore SG; Regua AT; Lo HW
    Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36360302
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
    Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
    Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Spotlight on Patritumab Deruxtecan (HER3-DXd) from HERTHENA Lung01. Is a Median PFS of 5.5 Months Enough in Light of FLAURA-2 and MARIPOSA?
    Arter ZL; Nagasaka M
    Lung Cancer (Auckl); 2024; 15():115-121. PubMed ID: 39011085
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
    Tamura K; Tsurutani J; Takahashi S; Iwata H; Krop IE; Redfern C; Sagara Y; Doi T; Park H; Murthy RK; Redman RA; Jikoh T; Lee C; Sugihara M; Shahidi J; Yver A; Modi S
    Lancet Oncol; 2019 Jun; 20(6):816-826. PubMed ID: 31047803
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Potent antitumor activity of anti-HER2 antibody-topoisomerase I inhibitor conjugate based on self-immolative dendritic dimeric-linker.
    Liubomirski Y; Tiram G; Scomparin A; Gnaim S; Das S; Gholap S; Ge L; Yeini E; Shelef O; Zauberman A; Berger N; Kalimi D; Toister-Achituv M; Schröter C; Dickgiesser S; Tonillo J; Shan M; Deutsch C; Sweeney-Lasch S; Shabat D; Satchi-Fainaro R
    J Control Release; 2024 Mar; 367():148-157. PubMed ID: 38228272
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeting the EGF receptor family in non-small cell lung cancer-increased complexity and future perspectives.
    Boch T; Köhler J; Janning M; Loges S
    Cancer Biol Med; 2022 Dec; 19(11):1543-64. PubMed ID: 36476337
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
    Ferraro E; Drago JZ; Modi S
    Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy with Trastuzumab Deruxtecan for Non-Small-Cell Lung Cancer Harboring
    Kato Y; Kato Y; Minegishi Y; Suzuki T; Nakamichi S; Matsumoto M; Miyanaga A; Noro R; Kubota K; Terasaki Y; Seike M; Gemma A
    Onco Targets Ther; 2021; 14():5315-5319. PubMed ID: 34848974
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mechanisms of resistance to HER family targeting antibodies.
    Kruser TJ; Wheeler DL
    Exp Cell Res; 2010 Apr; 316(7):1083-100. PubMed ID: 20064507
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges.
    Guidi L; Pellizzari G; Tarantino P; Valenza C; Curigliano G
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831473
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting HER2 alterations in non-small cell lung cancer: Therapeutic breakthrough and challenges.
    Yu Y; Yang Y; Li H; Fan Y
    Cancer Treat Rev; 2023 Mar; 114():102520. PubMed ID: 36738637
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Exploring DESTINY: the Past, Present, and Future of Trastuzumab Deruxtecan.
    Ali A; Graff SL
    Curr Oncol Rep; 2024 Jan; 26(1):1-9. PubMed ID: 38091201
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antibody-Drug Conjugates in Gynecologic Cancer.
    Karpel HC; Powell SS; Pothuri B
    Am Soc Clin Oncol Educ Book; 2023 May; 43():e390772. PubMed ID: 37229642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.